Funding for this research was provided by:
MSD Sharp & Dohme GmbH
Universitätsklinikum Hamburg-Eppendorf (UKE)
Received: 14 January 2021
Accepted: 9 August 2021
First Online: 28 August 2021
: All patients have given written informed consent, and the trial was approved by the ethics committee at the Christian Albrechts University of Kiel.
: Not applicable.
: CB has received speaker honoraria, research grants, awards, and/or travel expenses from Celgene, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Stiefel Laboratories, The EuroQol Group, and Urgo. KCK serves as consultant to Roche, BMS, MSD and received travel grants and speaker fees from Roche, BMS, MSD, GSK, Amgen, Array. TW has no conflict of interest. AH serves as consultant to Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, Oncosec, Eisai and received speaker fees, travel grants, and research funding from Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, Oncosec, and Eisai. MA has received grants and/or honoraria as a consultant, speaker, and/or advisory board member from Almirall, DAK, and Leo.